Testing trehalose and small blood vessel function in adults with type 2 diabetes
Tests trehalose, compared with placebo, on small blood vessels in adults with diabetes.
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Registry title
- Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 60 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Trehalose
- Placebo
- Record updated
- 30 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Type 2 Diabetes and otherwise healthy adults with no more than 1 cardiovascular risk factor. It studies how autophagy affects the function of small blood vessels.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 Diabetes diagnosed in line with American Diabetes Association (ADA) guidelines, or otherwise healthy people with no more than 1 cardiovascular risk factor.
- Earlier treatment
- People cannot join if they used anti-coagulant or anti-platelet drugs, hormone replacement therapy, or steroids in the last 6 months. Anti-cancer treatment in the last 12 months also rules people out.
Main reasons for not taking part
- Type 1 Diabetes
- Current tobacco use or use within the last 6 months
- BMI above 35
- Uncontrolled hypertension, symptomatic coronary artery disease, or heart failure
- Active COVID-19 or COVID-19 within the past 3 months
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
- Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor
Who cannot take part
- Hormone Replacement Therapy
- Use Erectile Dysfunction Medication in the past 6 months
- Use of Topical/non-topical Steroids in last 6 months
- Gender Reassignment Therapy
- Uncontrolled hypertension
- Type 1 Diabetes
- Symptomatic coronary artery disease
- Heart Failure
- Renal Impairment
- History of Retinopathy
- Documented Neuromuscular Disorders
- Allergies to Povidone Iodine
- Active Anti-Cancer Treatment or Treatment within last 12 months
- Active COVID-19 or within the past 3 months
- Use of anti-coagulant drugs, or anti-platelet drugs
- Current Tobacco use or within last 6 months
- BMI > 35
- Hyperlipidemia
- Hypercholesterolemia
- Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
- Pregnancy (Young Female subjects)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Medical College of WisconsinMilwaukee, United StatesContact: William Hughes, Ph.D.Taking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are:
Read full original descriptionShow less
* Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function?
Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.
The 2 groups in the trial
- TrehaloseTreatment being tested
10g mixed in 500 mL of water, consumed 1 time per day
- PlaceboPlacebo, for comparison
10g microcrystalline cellulose in 500 mL, consumed 1 time per day
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
- Plain-language title
- Testing trehalose and small blood vessel function in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05593549, who can take part
- Record updated
- 30 October 2025